Functional analysis of human alpha 1(I) procollagen gene promoter. Differential activity in collagen-producing and -nonproducing cells and response to transforming growth factor beta 1. by Jimenez, Sergio A. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medicine Faculty Papers Department of Medicine
4-29-1994
Functional analysis of human alpha 1(I)
procollagen gene promoter. Differential activity in
collagen-producing and -nonproducing cells and
response to transforming growth factor beta 1.
Sergio A. Jimenez
Thomas Jefferson University, Sergio.Jimenez@jefferson.edu
John A. Varga
Thomas Jefferson University
Anne Olsen
Thomas Jefferson University
Liye Li
Thomas Jefferson University
Arturo Diaz
Thomas Jefferson University
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/medfp
Part of the Rheumatology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Jimenez, Sergio A.; Varga, John A.; Olsen, Anne; Li, Liye; Diaz, Arturo; Herhal, Janet; and Koch,
Julie, "Functional analysis of human alpha 1(I) procollagen gene promoter. Differential activity in
collagen-producing and -nonproducing cells and response to transforming growth factor beta 1."
(1994). Department of Medicine Faculty Papers. Paper 186.
https://jdc.jefferson.edu/medfp/186
Authors
Sergio A. Jimenez, John A. Varga, Anne Olsen, Liye Li, Arturo Diaz, Janet Herhal, and Julie Koch
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medfp/186
THE JOURNAL OF BIOUXICAL CHEMISTRY 
0 1994 by The American Society for Bioehemistry and Molecular Biology, Inc. 
Vol. 269, No. 17, Issue of April 29, pp. 12684-12691,  1994 
Printed in U.S.A. 
Functional  Analysis of Human d ( 1 )  Procollagen  Gene  Promoter 
DIFFERENTIAL ACTIVITY IN  COLLAGEN-PRODUCING  AND  -NONPRODUCING CELLS AND RESPONSE TO 
TRANSFORMING  GROWTH FACTOR &* 
(Received  for publication, December 30, 1993) 
Sergio A. JimenezSJn 1, John VargaS, Anne Olsen§n**, Liye  Lis, Arturo DiazS, Janet HerhalS, and 
Julie Koch$ 
From the Departments of medicine  and $Biochemistry and Molecular Biology and the Wnstitute of Molecular  Medicine, 
Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 
To gain a further understanding of the regulation of 
human type I collagen gene expression under physi- 
ologic and pathologic  conditions, we characterized 5.3 
kilobase pairs (kb) of the human d(1) procollagen  gene 
promoter. A series of deletion constructs containing  por- 
tions of the d(1) procollagen  5’-flanking  region  (with 
end points from  -5.3 kb to -84 base pairs (bp)) ligated to 
the chloramphenicol acetyltransferase (CAT) reporter 
gene were transiently transfected into NIW3T3 cells. 
Maximal CAT activity was observed with constructs 
having 5’ end points from -804 to -174 bp. A further 5’ 
deletion to -84 bp  caused a marked reduction in CAT 
activity.  Cells transfected with  plasmids containing 
longer S’-flanking fragments of the al(1) procollagen 
gene (-2.3 or -5.3 kb)  showed  reduced CAT activity com- 
pared with the -804 bp construct. The  activity of the 
al(1) procollagen  promoter  was  much  lower in cells that 
do not normally express type I collagen (HeLa cells) 
compared  with  collagen-producing  NW3T3  cells.  The 
CAT activity of deletion constructs containing longer 5‘ 
regions than -84 bp  was increased by = 2-fold in NIW3T3 
cells treated with transforming growth factor p l  
(TGFf.31). Electrophoretic mobility shift assays indicated 
that protein-DNA  complex  formation  with a probe  cor- 
responding to  the -170 to -80 bp  fragment of the al(1) 
procollagen  promoter  was  markedly  enhanced in 
nuclear extracts prepared from TGFpl-treated fibro- 
blasts as compared  with untreated fibroblasts.  The DNA 
binding activity stimulated by TGFpl  was  specific  for an 
Spl-like sequence at positions -164 to -142 bp in the pro- 
moter.  These results demonstrate that 1) there  are both 
positive and negative  cis-acting regulatory elements in 
the human al(1) procollagen  promoter, 2) these regula- 
tory regions function differently in collagen-producing 
and -nonproducing  cells,  3) the cul(1) procollagen  pro- 
moter contains TGFpl-responsive  sequences  located  be- 
tween -174 and -84 bp  from the transcription start site, 
and 4) TGFpl  caused  marked stimulation of the DNA 
binding  activity of a nuclear factor interacting with an 
Spl-like binding site located within a region  encompass- 
ing -164 to -142 bp of the al(1) procollagen  promoter. 
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Normal fibroblasts modulate their biosynthetic activity to 
maintain a precise balance  between  the  synthesis  and  degra- 
dation of their  products  during dynamic events of tissue remod- 
eling  such as development,  differentiation, and  repair. It has 
been  suggested that abnormalities in these  regulatory  mecha- 
nisms  may be  responsible for the excessive extracellular  matrix 
accumulation in a variety of fibrotic diseases  such as systemic 
sclerosis and idiopathic pulmonary fibrosis. 
The collagens  comprise a large family of widely distributed 
proteins that play a crucial role in the maintenance of the 
structural  properties of the  extracellular  matrix. Despite the 
important structural and functional roles that the collagens 
play in normal tissues, the mechanisms that regulate their 
production are not completely understood. Variations in  net 
collagen production  occurring during  growth  and differentia- 
tion (1-31, viral  (4-6)  and chemical (7-9) transformation, cyto- 
kine  and  growth factor  modulation (10-14), and  spontaneous 
(15-17) and  experimentally induced (18, 19) fibrotic  processes 
have  been ascribed to  fluctuations  in  the  steady-state collagen 
mRNA levels. The  regulatory  mechanisms responsible for the 
maintenance of normal procollagen mRNA levels have  not  been 
completely elucidated. Most of the  available evidence suggests 
that the principal mechanisms  operate at the level of transcrip- 
tion,  although  translational control and  changes  in mRNAproc- 
essing  and  stability  may  also play a role  (reviewed in Refs. 20 
and 21). The broad spectrum of regulatory signals that can in- 
fluence collagen gene  transcription  suggests that the collagen 
gene  promoters  are responsive to  various  trans-acting  path- 
ways. Several  putative  regulatory  elements  that  may  determine 
the  transcriptional efficiency of procollagen genes have  been 
identified in  their corresponding  promoters. These include the 
consensus TATA and CCAAT motifs as well as additional  regu- 
latory  elements (22-251, which are  the  potential  targets for the 
action of promoter-specific transcription  factors (26-31). Fur- 
thermore,  the  transcriptional activity of some procollagen gene 
promoters appears  to be modulated by enhancer  and  silencer 
elements located 3‘ from the  transcription start site (32, 33). 
Detailed characterization of the cis-acting elements involved 
in modulation of collagen gene expression is crucial for under- 
standing  the physiologic and pathologic regulation of tissue 
collagen deposition. The purpose of the work reported  here  was 
to  analyze  the  human crl(1) procollagen gene  promoter  in  order 
to identify regulatory regions of the  gene that may play  a role 
in the modulation of its expression under  normal  and patho- 
logic conditions. 
MATERIALS AND METHODS 
Construction  ofPlasmids“Severa1  preliminary steps were  necessary 
to prepare  fragments with the appropriate  restriction sites for ligations. 
The  Hind111 site in pSV0 CAT’ was  changed to a KpnI site, and a 1.6 kb 
The abbreviations used are: CAT, chloramphenicol acetyltrans- 
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KpnI-EamHI  fragment  was  isolated.  A  7  kb aUI)procollagen gene  KpnI 
fragment  extending from -5.3 to  +1.7  kb  was  isolated  from a human 
cosmid clone2 and  subcloned  into pUC19, and  the  KpnI  site  at -5.3 kb 
was  changed to a  NotI  site  to give pJH49.  A  HindIII-ThaI  fragment, 
extending from -804 to +42  bp,  was  subcloned  into  the  HindIII  and 
SnaI sites of pUC19, excised as a HindIII-KpnI  fragment,  and  sub- 
cloned into the HindIII and KpnI sites of Bluescript KS+ to  give 
p804BS. The 4.5 kb NotI-Hind111 fragment from pJH49 (containing 
al(1) procollagen gene  sequences  from -5.3 kb  to -804 bp)  was  then 
subcloned into  the  NotI  and  HindIII  sites of p804BS to give p5.3kBS. 
For  the -5.3 and -804 bp  constructs,  the  NotI-KpnI  fragments  from 
p5.3kBS  and p804BS were  ligated  with  the 1.6 kb  KpnI-EarnHI CAT 
coding fragment  into  the  NotI  and  BamHI  sites of Bluescript KS+ to 
give p5.3kal CAT and  p804al CAT, respectively. For  the  2.3  kb con- 
struct, a 1.5  kb BarnHI-Hind111 fragment  containing  sequences from 
-2.3 kb to -804 bp was converted to a NotI-Hind111 fragment and 
inserted  into  the  Not1  and  HindIII  sites of p804al CAT to give p2.3kal 
CAT. A  series of deletions  (from the  HindIII  site at -804 bp  in  p804al 
CAT toward the start of transcription site) was made following the 
exonuclease 111 digestion  procedure of Henikoff (34).  Exact  deletion  end 
points  were  determined by sequencing, and clones ending at -675, -463, 
-369, -174, and -84 bp  were  selected for analysis.  A  promoterless CAT 
plasmid, pOCAT, was  prepared by removing the  846  bp  HindIII-KpnI a1
procollagen promoter  fragment  from  p804al CAT and religating. 
The  sequence from -2.3 kb  to -804 bp of the al(1) procollagen gene 
was  obtained  from  deletions  made from the  NotI  site  in  p2.3kal CAT 
toward  the  initiation of transcription  site  (also following the exonucle- 
ase I11 digestion  procedure). DNA sequencing of both strands  was  per- 
formed using the dideoxy chain termination procedure (35) with T7 
polymerase  (Sequenase, U. S. Biochemical Corp.) following the  instruc- 
tions provided by the  supplier. 
Cell ~ansfections-NIW3T3 cells (obtained from the ATCC) from 
subconfluent  cultures  were  plated a t  a  density of 3 x lo5 celld60-mm 
dish and cultured in Dulbecco's modified Eagle's medium containing 
10% calf serum.  Transfections  were  performed 24 h later employing the 
calcium  phosphate  co-precipitation  method, as described  (36).  The  NIW 
3T3  cells  were  transfected  with  4 pg of al(1) procollagen promoter-CAT 
plasmid DNA and 0.2 pg of the pSV2AP plasmid DNA containing  the 
SV40 early  promoter and  enhancer  fused  to  a  rat  alkaline  phosphatase 
cDNA (kindly provided by Dr. Kyong Yoon) (37) as an  internal  standard. 
m e r  4  h,  the  cultures  were  subjected  to  a 15% glycerol shock for 3 min 
at room temperature  and  then  grown  in  fresh  medium for 48 h before 
harvesting.  HeLa  cells  (obtained from the ATCC) were  plated  in  60-mm 
plastic culture dishes (3 x lo5 cellddish), and 16 h later they were 
transfected  with  the  plasmids  with  the  same  procedure  as  that  used for 
NIW3T3 cells, except that  HeLa  cells  were  cultured  in  minimum  Ea- 
gle's medium containing 10% fetal calf serum  instead of calf serum 
following the glycerol shock. 
Effects  of TGFpI-To investigate  the  effects of TGFpl on the  expres- 
sion of the  various al(1) procollagen promoter  constructs,  NIW3T3 cells 
were  transfected  with  the  deletion  construct  plasmids  and  the pSV2AP 
control  plasmid as described above. Six  hours  aRer  the  transfections, 
the  culture  media  were  removed,  and  a  fresh  medium  containing 10% of
the  serum  substitute  Serum  Plus  (Hazelton Biologics) and 12.5 ng/ml 
human  recombinant  TGFpl  (NIH  Bureau of Standards, or R & D  Sys- 
tems)  was  added  to  duplicate  cultures.  Control  cells  incubated  in  par- 
allel received culture  medium  without  TGFp1.  The  control  and  TGFp1- 
treated  cells  were  incubated for an  additional  48  h  and  then  harvested 
for assays of CAT and alkaline phosphatase activities as described 
below. 
Assays of CAT and Alkaline  Phosphatase Actiuities-Cell extracts 
were  prepared by mechanically  detaching the cells  in 1.5 ml of phos- 
phate-buffered  saline  and by centrifugation a t  5000 x g for 3 min. The 
cell pellets  were  resuspended in 100  pl of 0.25 M Tris-HC1, pH  7.8,0.1% 
Triton X-100 and  sonicated for 15 s. CAT activity  was  measured on 20-111 
aliquots of supernatants following centrifugation of the  extracts for 5 
min  in a Microfuge. The  supernatants were  heated for 10 min a t  60 "C 
prior  to the  assay of  CAT activity by a  liquid  scintillation  assay  using 1 
pCi of [3Hlacetyl-CoA/sample as  described  (38). In some  experiments, 
CAT activity  in  the cell extracts  was  determined  employing [14C]chlor- 
amphenicol  according  to the method  described by Gorman  et  al.  (39). 
The conversion of chloramphenicol  to  acetylated  forms  was  quantified 
by scraping  the  corresponding  areas  from  the  thin  layer  chromatogra- 
phy  plates  and  measuring  radioactivity by liquid  scintillation  spectros- 
copy. The two methods of assaying CAT activity yielded comparable 
ferase;  kb,  kilobase  pairb);  bp,  base  paids). 
J. Hyland,  unpublished  observations. 
results.  Alkaline  phosphatase  activity  was  assayed on 5  pl of the ex- 
tracts as described by Yoon et al. (37). CAT activity in  each  sample  was 
normalized to alkaline  phosphatase  activity  to  correct  for  differences  in 
transfection efficiency. 
Electrophoretic Mobility Shift Assays-Nuclear extracts were pre- 
pared from confluent  cultures of normal  human  skin  fibroblasts  that 
had been incubated with or without TGFpl (1 or 10 ng/ml) in the 
presence of 5% fetal calf serum for 48  h  according to  the method of 
Dignam  et  al.  (40).  Protein  concentrations  were  determined by a dye 
binding  assay (Bio-Rad), and  the  nuclear  extracts  were  stored  in  50-pl 
aliquots a t  -70 "C until  use.  In  order  to  ensure  that  fibroblast  protein 
biosynthesis was stimulated by TGFPI, cultures were labeled with 
[14Clproline (1.5 pCi/ml) for 24 h prior to harvesting. Only nuclear 
extracts prepared from cultures exhibiting a greater than 2-fold in- 
crease in ['4Clproline-labeled protein production over untreated cul- 
tures were  used.  In  a  typical  experiment, a confluent 175-cm flask (lo7 
cells) yielded -100 pg of crude  nuclear  protein. 
Probes for electrophoretic mobility shiR assays were prepared by 
enzymatic  digestion of the  p804alCAT  plasmid  with  NotI  and  KpnI. 
The  resulting  431 bp fragment  was  gel-purified  and  further  digested 
with NaeI and Hinfl. The  resulting  219  bp NotI-Hinff (200-3) and 90  bp 
Hinff-NueI (200-2) fragments were purified and 5' end-labeled with 
[a-32PldCTP  using the Klenow fragment of DNApolymerase I according 
to  conventional  procedures  (41).  Additional oligonucleotide probes  were 
prepared by automated DNA synthesis (Applied Biosystems),  and oli- 
gonucleotide S p l  was  obtained from Stratagene.  Each oligonucleotide 
was  annealed to its complementary strand  and end-labeled  with 
[y3'P1ATP using T4 polynucleotide kinase (Boehringer Mannheim). 
Competition  studies  were  performed  with  molar  excesses of unlabeled 
DNA fragments or double-stranded oligonucleotides. Electrophoretic 
mobility assays were performed using low ionic strength buffers as 
described  (42).  Binding  reactions  contained 5-10 pg of the  nuclear ex- 
tracts, 1-2 pg of double-stranded poly[d(I-C)I (Pharmacia LKB Biotech- 
nology Inc.), and  radiolabeled  probes  containing 50,000 cpm for a  total 
of approximately 0.5 ng. The  reaction  mixtures were incubated for 30 
min on ice in a buffer containing 60 m KCl, 10 m HEPES  pH 7.9, 1 
l l l ~  dithiothreitol, 1 m EDTA, and 5% glycerol in a total volume of 10 
p1. Protein-DNA complexes were resolved from the free  probes  in  non- 
d naturing  5%  polyacrylamide  gels.  Electrophoresis  was  performed  in 
Tridglycine  buffer (50 m Tris-HC1, 260 m glycine) at  120  V for 120 
min.  The  gels  were  dried  under  vacuum  and exposed to  x-ray film with 
intensifying  screens at -70 "C for 1648 h. 
RESULTS 
Nucleotide Sequence of -2.3 kb  to -804 bp Region of al(Z) 
Procollagen Gene-The nucleotide sequences of the human 
al(I) procollagen  promoter and 5"flanking  region  to -804 bp 
have been previously reported (23). Our results extend the 
upstream sequence of the gene to the BarnHI site at  -2.3 kb 
(Fig. 1). The only species for which the al(1) procollagen se- 
quence in this area has been reported to date is rat (43). A 
comparison of the nucleotide sequences of human and rat al(1) 
procollagen gene 5"flanking regions indicates a relatively low 
overall nucleotide identity (62%). However, there are several 
regions within the human and rat sequences (underlined in 
Fig. 1) that are greater than 90% identical. A search of all 
mammalian DNA sequences in GenBank (release 80.0) re- 
vealed no additional sequences of identity or high homology  to 
either strand of the new upstream sequence reported here. 
Deletion Analysis of 5.3 kb  Upstream  Sequence of the al(I) 
Procollagen Gene-To analyze sequences that may be impor- 
tant for regulation of  collagen gene expression, a series of  CAT 
constructs with 5' end points from -5.3 kb to -84 bp were 
prepared (Fig. 2) and examined in transient transfection assays 
of  functional activity. To eliminate the al(1) procollagen gene 
ATG initiation codon at +120 bp and the two additional up- 
stream ATG codons at  +lo3 and +61  bp, the 3' end point  of all 
fragments was +42 bp. Therefore, translation should initiate 
only at the ATG codon of the CAT gene. The plasmids were 
transfected into NIW3T3 cells, and cell extracts were analyzed 
for CAT activity. To control  for differences in transfection effi- 
ciency between samples, all results were normalized to a co- 
transfected reference  plasmid (pSV2AF'). A  summary of these 
12686 Human al(0 Procollagen Gene Promoter 
5"flanking region of the  human al(1) 
FIG. 1. Nucleotide  sequence of the 
BarnHI-Hind111 fragment encompassing 
procollagen  gene. The  sequence of the 
positions -2292 to -798 bp is shown. Re- 
gions with greater than 90% identity to 
the corresponding rat sequences (43) are 
underlined. 
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AQQACQTQQAQTTCTAQAQCCATCTTCCTTAQATATAQCCTQCTQTCCTTCQQQTCCCCAQACCCTTTCA 
QAQTQTACAQATQATTCTCTCTQQTTCCTAAQQCATAQAQCAATQACCQQQATTTTCAAQAAAQAQATQA 
QQCAQTQQQAAQTAQCCCCTAAAACAAAQTCAATCATCCTCTQCAQCCCATCCCACACCCCCAAAQQAAA 
QTTTCACCCAQACACCCAAAATATCCCATACATCCCCAACACTQAQTCCAQQTACAACTQQAQAAQQQQC 
TTTATQCAQCTCCCAQAAAQACACCCCTTTAQCTAAQTQCCCTCCCTCCACCCAQQTTCTCTCTQQTTTQ 
ACTQTQCTQQQAAQQAQQQTCTCTAAQCAQCCCCTQQCCACAQCCATQQCAAACAAAACTCTTCTCTAAQ 
TCACCAATQATCACAQQCCTCCCACTAAAAATACTTCCCAACTCTQQQQTQQAAQAQTTTQQQQQATQAA 
TTTTTAQQQQATTQCAAQCCCCAATCCCCACCTCTQTQTCCCTAQAATCCCCCACCCCTACCTTQQCTQC 
TCCATCACCCAACCACCAAAQCTT 
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FIG. 2. Summary of CAT activity  driven by various  lengths of the  5'-flanking  sequence of the human al(1) procollagen gene. A 
schematic linear map of p5.3Kal CAT and 5' end points of the deletion constructs are shown on the left. NIW3T3 cells were transiently 
co-transfected with the al(1) procollagen-CAT constlvcts containing various lengths of promoter sequences and the alkaline phosphatase-CAT 
construct; CAT and alkaline phosphatase activities were determined as described  under  "Materials  and  Methods."  The atched bars on the right 
represent CAT activity driven by each construct  corrected for alkaline phosphatase activity in the same extracts relative to the CAT activity of the 
-804 bp construct. Plasmids were assayed in at least two separate transfection experiments with duplicate or triplicate determinations in each, 
except for the -675 bp construct, which was used in duplicate in a single experiment. Values shown represent the average f S.E. 
experiments is shown in Fig. 2. The results indicate that CAT 
expression was maximal and constant in cells transfected with 
promoter constructs having 5' end points from  -804 to -174  bp. 
A further  3' deletion to -84  bp caused a significant reduction in 
CAT activity, although even this  short promoter was able to 
drive 10-fold higher CAT activity than  the promoterless CAT 
plasmid pOCAT. Plasmids containing longer 5' fragments (ex- 
tending to -2.3 or -5.3 kb) showed  lower CAT activity than  the 
-804  bp construct (50 and 20%, respectively). 
Comparison of Activity of d(I) Procollagen  Promoter in Col- 
lagen-producing  and -nonproducing Cells-In order to assess 
the activity of cul(1) procollagen  promoter sequences in  a cell 
line that does not normally exhibit high levels of type I collagen 
gene production, constructs with end points at -5.3 kb, -2.3 kb, 
and -804  bp  were transfected into HeLa  cells. As shown in Fig. 
3, the CAT activity driven by these three constructs was mark- 
edly lower in HeLa  cells than in NIW3T3  cells. In NIW3T3 
cells, CAT activity driven by the -804  bp construct was about 
26-fold higher than  the CAT activity observed with the promot- 
erless construct pOCAT, whereas in HeLa cells the relative 
activity of the -804  bp construct was 10-fold  lower. In contrast 
to NIW3T3  cells, transfection of constructs with longer 5' se- 
quences into HeLa  cells resulted in about 2-fold greater CAT 
activity than  that obtained with the -804  bp plasmid. These 
results suggest that  the positive and negative transcriptional 
regulatory regions of the cul(1) procollagen  promoter function 
differently in collagen-producing and -nonproducing  cells. 
Localization of d(I) Procollagen  Promoter Regions Respon- 
sive to TGFPl-In order to localize regions within the al(1) 
procollagen promoter that are responsive to stimulation by 
TGFPl  in the NIW3T3 cells, the effects of TGFPl on the CAT 
activity in cells transfected with promoter deletion constructs 
with 5' end points at -5.3 kb, -2.3 kb, and -804 bp were 
examined. Incubation with TGFpl for 48 h resulted in an ap- 
proximately 2-fold stimulation of CAT activity in cells trans- 
fected with each of the  three constructs (Fig. 4), suggesting that 
TGFpl-responsive elements were  located within the proximal 
region of the promoter 3' to the -804  bp end point. To further 
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in collagen-producing (NW3T3) and -nonproducing (HeLa) 
FIG. 3. Activity of the human al(1) procollagen gene promoter 
cells. Cultured NIW3T3 and HeLa cells were transiently transfected 
with various deletion constructs (described in the legend to Fig. 2) 
under identical conditions. CAT activity in the cell extracts was deter- 
mined following a 48-h incubation, as described under "Materials and 
Methods." CAT activity driven by the individual constructs corrected for 
transfection efficiency, as determined by alkaline phosphatase activity 
in  the same samples, is shown relative to the CAT activity of the pro- 
moterless plasmid pOCAT. The values shown represent the average * 
S.E. of three separate transfections with each plasmid, each assayed in 
duplicate. 
rl 
r-+ I I  
-5.0 -2.3 4.8 0 
DELETION  ENDPOINT 
FIG. 4. Effects of TCFfll on CAT activity driven by various 
lengths of the  S'danking sequence of the human al(1) procol- 
lagen gene. NIW3T3  cells  were transiently transfected with the pro- 
gressive deletion constructs derived  from the p5.3KBS plasmid, as de- 
scribed under "Materials and Methods," and incubated in Dulbecco's 
TGFpl(12.5 ng/ml) for 48 h. CAT activity of the cell extracts, corrected 
modified  Eagle's medium containing 10% Serum  Plus with or without 
for alkaline phosphatase activity, is shown relative to the -804 bp 
construct. 
identify TGFpl-responsive sequences within the proximal re- 
gion of the al(1) procollagen promoter, NIW3T3 cells were 
transfected  with  constructs  with 5' end points a t  -675, -463, 
-369, -174, and -84 bp or with the promoterless construct 
pOCAT and incubated  with TGFp1. The results indicate that 
TGFpl caused a greater  than 2-fold increase in CAT activity 
driven by the constructs  with 5"flanking regions longer than 
-84  bp. In contrast, TGFpl did not stimulate  the CAT activity 
driven by the -84 bp promoter. A representative  transfection 
experiment is shown in Fig. 5. These results indicated that 
TGFpl-responsive sequences are located between -174 and 
-84  bp of the al(1) procollagen  promoter. 
Nuclear Protein Binding to d ( Z )  Procollagen Promoter in 
Control and TGFpl-treated Fibroblasts-In order to elucidate 
A 
Plasmid deletion 
-369 bP  -174 bp endpoint , ,, ,, -84 bp , 
TGFn - + 
Acetylation (%) 3.6 163 3.6 133 1.7 21 
- + -  + 
T T T 
-675  -463 -369 -174 
1)eletion endpoint (bp) 
FTG. 5. Regulation of the al(1) procollagen promoter  activity 
by TFGfl1. A, representative CAT assay demonstrating the effect of 
TGFpl on three deletion constructs of plasmid P804al CAT. NIW3T3 
cells were transfected with the -369,  -174, and -84  bp end point con- 
structs. Following a 48-h incubation with or without TGFp1, CAT ac- 
tivity in the cell extracta was determined as described under "Materials 
and Methods." Values are expressed as percentage of [14Clchloram- 
phenicol that was acetylated. B, histogram showing results of transient 
transfections of deletion constructs from four separate experiments. 
CAT activity in TGFpl-treated cells (mean countdmin 2 S.E. from 
duplicate determinations) is expressed relative to the CAT activity in 
untreated cells (100%). 
changes in trans-acting protein-DNA interactions involving the 
al(1) procollagen promoter that were associated with TGFp1- 
induced stimulation of collagen production, electrophoretic mo- 
bility shift assays were performed. For this purpose, nuclear 
extracts were prepared from untreated  and  TGFpl-treated fi- 
broblasts. Two fragments (200-2 and 200-3) of the al(1) procol- 
lagen promoter region spanning  the sequences from -389 to 
-80 bp relative to the transcription start site were used as 
probes (Fig. &I). Incubation of the 200-2 probe (-170 to -80 bp) 
with nuclear extracts from untreated or TGFpl-treated cells 
resulted in  the formation of two complexes with retarded elec- 
trophoretic mobility (labeled R1  and R2), indicating the pres- 
ence of nuclear DNA binding factorb) recognizing sequences 
within the probe (Fig. 7). The intensity of the R1 and R2  com- 
plexes determined by laser densitometry of the autoradiograms 
was increased 18- and 8-fold, respectively, when nuclear ex- 
tracts prepared from fibroblasts that  had been treated with 
TGFpl(10 ng/ml) were used (Fig. 7). Competition experiments 
indicated that a 4-fold molar excess of unlabeled 200-2 probe 
completely prevented the formation of the R1 complex and re- 
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B 
sPl.1 5'- CTCCCTCCTCCTCCCCCTCTCC -1 641-142 
SP1.2 5" GGGCACGGGCGGCCGGC 
AP-1.1  5'-CCCACCTGAGGGAAGG 
NF-1.1 5'- CTAACCGACCCCGGGCCC 
GC 5' -ATTCGATCGGGGCGGGGCGAGC 
-931-77 
-1751-160 (reverse) 
-1 02/-85 (reverse) 
FIG. 6. Locations  and  sequences of the probes used  in  electro- 
phoretic  mobility  shift  assays. A, 200-2 and 200-3 fragments  and  the 
Spl-, AP-1-, and NF-1-like elements in  the proximal region of the al(1) 
procollagen promoter are shown. The arrow indicates the transcription 
start site. B,  nucleotide sequences of the sense (Spl.1  and Sp1.2) or 
antisense ("1.1 and NF-1.1) strands of the binding site oligonucleo- 
tides used. The core motifs are shown in boldface. The GC-box oligo- 
nucleotide contains the Sp l  consensus binding sequence. 
Competitor 0 0 0 4 2 5  
TCFBI (11gIm1) 0 1 10  0 10 
*' > 
R t  
FIG. 7. .Electrophoretic  mobility  shift  assay with competing 
unlabeled DNA. A90 bp double-stranded fragment of the  human crl(1) 
procollagen gene promoter encompassing the sequence from positions 
-170 to -80 bp (200-2) was end-labeled and used as a probe in electro- 
phoretic mobility shift assays. Labeled probes were incubated  with 1 pg 
of poly[d(I-C)l and  5  pg of nuclear extracts prepared from normal hu- 
man dermal fibroblasts that  had been treated with TGFpl (1 or 10 
ng/ml) or left untreated for 48 h. Reactions were carried out  in  the 
absence or presence of 4- and 25-fold molar excesses of unlabeled 200-2 
DNA probe, and  the formation of DNA-protein complexes was analyzed 
by electrophoresis in 5% polyacrylamide gels under nondenaturing con- 
ditions. The two  slowly migrating DNA-protein complexes are labeled 
R l  and R2. Lane 1, control containing the labeled probe but no protein. 
duced by about 60% the formation of the R2 complex with the 
labeled 200-2  probe. A 25-fold molar excess of unlabeled 200-2 
probe did not completely prevent the formation of the R2  com- 
plex (Fig. 7). These results suggest substantial differences in 
the DNA binding affinities of these  nuclear proteins. Several 
DNA-protein  complexes were detected when nuclear  extracts 
were incubated with probe  200-3, spanning the sequences from 
-389 to -170 bp (results not shown). However, in  contrast o the 
results obtained with the 200-2  probe, no qualitative or quan- 
titative differences in DNA-protein complex formation were 
noted when the binding of nuclear proteins prepared from un- 
treated or TGFpl-treated cells to the 200-3 probe was exam- 
ined. The  increase in nuclear binding activity specific for the 
200-2 probe in extracts  prepared from TGFpl-treated cells sug- 
gested the enhancement of either  the synthesis or the DNA 
binding activity of trans-acting factors recognizing an ele- 
ment(s) located within the -170 to -80 bp region of the al(1) 
procollagen  promoter. 
Binding of Nuclear Proteins from Control or TGFpl-treated 
Fibroblasts to Oligonucleotides with  Spl-like Binding Se- 
quences-A detailed  analysis of the nucleotide sequence of the 
-170 to -80 bp region of the  human al(1) procollagen promoter 
revealed two regions of homology with consensus sequences 
recognized by the transcription factor Spl, here designated 
Spl.1  and Sp1.2 (44, 45). To determine  whether nuclear pro- 
teins from human fibroblasts may interact with  these Sp-1-like 
elements in  the al(1) procollagen promoter, electrophoretic mo- 
bility shift assays were performed with  synthetic double- 
stranded oligonucleotides corresponding to the  Spl.1  and Sp1.2 
sequences as well as with oligonucleotides corresponding to 
promoter sequences that display homology with the AP-1 and 
NF"1 consensus binding elements. The location and nucleotide 
sequences of these potential  regulatory  elements in  the al(1) 
procollagen promoter are shown in Fig.  6.  Upon incubation of 
the  Spl.1 probe with nuclear extracts  prepared from untreated 
fibroblasts, two distinct DNA-protein  complexes, designated R1 
(upper, a duplex) and R2 (lower), were detected (Fig. 8A). In 
nuclear extracts prepared from fibroblasts treated with TGFp1, 
a reproducible 4-fold increase in  the intensity of the R1 complex 
and a less consistent 30% increase in  the intensity of the R2 
complex were noted compared with the intensity of the corre- 
sponding complexes formed with nuclear extracts from un- 
treated fibroblasts. Essentially no complex formation was de- 
tected when Sp1.2 was used as the probe (Fig. 8A). To 
determine  whether the formation of the R1 and R2 complexes 
resulted from  specific protein interactions with the Spl.1 
probe, competition experiments  with  increasing  amounts of un- 
labeled oligonucleotides containing the Spl.1 or Sp1.2 se- 
quences or the  Spl consensus binding site were performed. As 
shown in Fig. 8B, the formation of the R2  complex was com- 
pletely prevented by the addition of excess unlabeled Spl.1 
oligonucleotide, whereas excess Sp1.2 or consensus Spl  oligo- 
nucleotides failed to compete for binding. In contrast, the for- 
mation of the R1 duplex was  markedly reduced by each of the 
three competitor oligonucleotides. Incubation of the nuclear 
extracts  with the AP-1.1 or NF-1.1 oligonucleotide probes re- 
sulted in  the formation of single DNA-protein complexes (Fig. 
8C). However, in  contrast  to results obtained  with the  Spl.1 
probe, there were no differences in  the intensities of protein- 
DNA complexes when nuclear extracts prepared from un- 
treated or from TGFpl-treated fibroblasts were used. These 
results indicate that a nuclear  trans-acting protein binds to the 
Spl.1 element at -164 to -142 bp on the  antisense  strand of the 
al(1) procollagen promoter and  that  this DNA binding activity 
is increased by treatment of human fibroblasts with TGFp1. An 
additional DNA-protein complex (R2) is formed with this  Sp-l- 
like  element, but  this binding activity is less consistently in- 
creased by TGFP1. 
DISCUSSION 
The mechanisms involved in  the regulation of collagen  pro- 
duction under normal or pathologic conditions are not com- 
pletely understood (reviewed in Refs.  20 and 21). Although the 
synthesis of most proteins in eukaryotic cells appears to be 
regulated at a transcriptional level, post-transcriptional 
events,  such as  the regulation of the stability of newly synthe- 
sized mRNA, may play an important role under  certain condi- 
tions (46,47).  Studies of the transcriptional  regulation of vari- 
ous collagen genes in  human  and rodent cells in vitro have 
demonstrated the presence of regulatory elements located im- 
mediately 5' upstream of the transcription  initiation site (22- 
26). In addition, an enhancer  element located within the first 
intron  has been identified in  the type I collagen genes (32-34). 
Sequences located far  upstream of the initiation of the  tran- 
scription site may also  be involved in  the regulation of expres- 
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sion of the collagen genes  (48, 49). Rippc et al. (49) analyzed 
murine al(1) procollagen gene  sequences  encompassing -3700 
to +1400 bp and found that a short  segment of the promoter 
(220  bp upstream from the start of the  transcription  site) was 
sufficient for expression of the gene,  whereas further  upstream 
flanking sequences had a negative effect on transcription. 
In  order  to identify upstream  elements  that may be involved 
in  the regulation of transcription of the  human al(1) procolla- 
gen gene, we determined  the nucleotide sequence of the pro- 
moter region encompassing from -804 to -2292 bp. Comparison 
of the newly obtained  sequence  with that of the promoter region 
in  the  rat crl(1) procollagen gene (43) indicated  less than 65% 
overall  nucleotide identity. However, several regions with 
highly conserved sequences in  the two species were found be- 
tween -1900 and -1540 bp (underlined in Fig. l). The high 
degree of nucleotide sequence conservation between the two 
species in  this region suggests  that  these sequences may have 
important regulatory functions. In  the rat gene, this region 
contains two repeats  that  are  variations of the palindromic 
of the  human gene  reported here demonstrated two identical 
palindromes localized at -1687 and -1063 bp. Other  putative 
regulatory  sequences  were  also identified in  the newly obtained 
sequence. These included two Spl  binding sites (GGGCGG) a t  
positions -2168 and -1614 bp and one NF-1  (half-site)  binding 
sequence (GCCAA) at position -830 bp (reverse  strand). 
I 
I sequence CCCTCCC. Analysis of the newly obtained  sequences 
d 
Spl.1  Spl  Spl.2 To perform a functional analysis of the  upstream sequences, 
c ' 0  2.5 100 250" 2.5 250" 2,5 several chimeric constructs containing DNA fragments  span- 
ning  up  to -5.3 kb of the al(1) procollagen promoter ligated to 
the CAT gene were prepared,  and  their expression was exam- 
ined following transient transfection into NIW3T3 cells. Maxi- 
mal transcriptional activity  was noted when promoter se- 
quences  with 5' end points from -176 to -804 bp were included. 
gressively decreasing  activity  (Fig. 2). These results  are  similar 
to those reported by Rippe et al. (49) for the murine al(1) 
procollagen gene. 
In  order  to examine if there were differences in  the regula- 
tion of al(1) procollagen gene transcription  in cells that consti- 
tutively produce high levels of collagen and cells that normally 
do not disdav exmession of interstitial collagen genes, we  com- 
- r m r  . "  " 
(I Constructs containing further  upstream sequences showed pro- 
C 
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R1 D 
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NF-1.1  AP .1 
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pared  the expression of the promoter-CAT constructs following 
their transfection into NIW3T3 cells or into HeLa cells. 
Marked differences in the expression of the promoter were 
observed between these two types of cells. Transfection of non- 
collagen-producing HeLa cells resulted  in relatively low levels 
of CAT activity, which, in  marked  contrast  to NIW3T3 cells, 
was increased when promoter  constructs  containing -2.3 and 
-5.3 kb  upstream sequences were examined  (Fig. 3). The dif- 
" 
17  bp Sp1.2 double-stranded oligonucleotides encompassing the  human 
al(1) procollagen promoter  sequences -164 to -142 bp or -93 to -77 bp, 
respectively, were end-labeled and used as  probes in electrophoretic 
mobility shift  assays.  Nuclear  extracts  were  prepared from normal hu- 
man  skin  fibroblasts  that  had  been  treated  with  TGFpl  (10 ng/ml) or 
left  untreated  for  48 h. Labeled probes were incubated with nuclear 
extracts  under  identical  conditions, as  described  in  the legend to Fig. 7. 
The  positions of the shifted complexes (Rl  and R2) are indicated,  along 
with  the position of the unbound DNA. Lane 1, control containing  la- 
beled Spl.1 probe but no protein. c, nuclear extract prepared from 
untreated  fibroblasts; T, nuclear  extract  prepared from TGFpl-treated 
fibroblasts. Panel B, same  as panel  A, except that only the  Spl.1 oligo- 
nucleotide  probe  and  increasing  concentrations (2.5-, loo-,  and 250-fold 
molar  excesses) of unlabeled  double-stranded competitor oligonucleo- 
tides  were  used.  Nuclear  extracts  were  prepared from TGFpl  (10  npl 
mbtreated fibroblasts,  except  in lane 2 (C,  untreated fibroblasts). Panel 
C, same  as panel A, except the "1.1 and NF-1.1 oligonucleotides, 
corresponding to the al(1) procollagen gene sequence from positions 
Sp1.2 probes and competitors. Panel A, the 23 bp Spl.1  and  the arrowhead denotes the retarded DNA-protein complex (RI). 
FIG. 8. Electrophoretic mobility shift assay with Spl.1 and -175 to -166 bp and -102 to -85-bp,respectIvely, were used. The 
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ferences in expression of the various constructs when trans- 
fected into collagen-producing and -nonproducing cell types 
suggest  that  the  intracellular milieu  plays an  important role in 
the regulation of the  rates at which the collagen genes  are 
transcribed.  Furthermore,  these  results suggest that cell-spe- 
cific transcriptional factors that  act on the  upstream sequences 
of the al(1) procollagen gene  may influence the expression of 
this gene. 
To further  investigate  the functional role that  the al(1) pro- 
collagen promoter  may  play during dynamic events  requiring 
remodeling of the  extracellular  matrix, we examined the effects 
of TGFpl on the expression of the  various promoter  constructs. 
It  has been suggested that  this growth  factor acting  in  auto- 
crine and paracrine fashion plays an  important role in the 
regulation of extracellular  matrix metabolism during develop- 
ment, differentiation, and  repair (reviewed in Refs. 50 and 51). 
TGFp  causes  marked accumulation of collagen in vivo and in 
vitro (52, 53). In  animal models of hepatic  and pulmonary fi- 
brosis, TGFp mRNA is expressed in high levels in  tissues prior 
to the development of fibrosis (54-56). Furthermore, recent 
observations implicate TGFp  in  the pathogenesis of various 
human diseases  characterized by exaggerated fibrosis (57-60). 
In  the  present study, we found that  TGFpl  stimulated CAT 
activity  driven by al(1) procollagen promoter constructs with 5' 
end points distal to -84 bp in  transiently  transfected NIW3T3 
cells. These results  indicate  that  TGFpl-responsive sequences 
in  the  human al(1) procollagen promoter are located between 
-174 and -84 bp from the  transcription start site. 
To determine if TGFpl induced alterations in DNA binding 
activity in fibroblasts, we examined DNA-protein complex for- 
mation in  nuclear  extracts  prepared from TGFpl-treated  and 
untreated cells by electrophoretic mobility shift  analysis  using 
DNA probes spanning  the proximal region of the al(1) procol- 
lagen promoter. The  results showed a marked increase in DNA 
binding  activity that was specific for the probe encompassing 
nucleotides -170 to -80 bp in  nuclear  extracts from TGFp1- 
treated cells. This region of the  human al(1) procollagen pro- 
moter contains a binding site for Spl  at -87 bp and  an  element 
with complete identity to the 3' portion of the canonical NF-1- 
binding motif (GCCAA), located in  reverse  orientation at -95 
bp. These  overlapping  potential  binding sites  have been shown 
to be important in the basal expression of the mouse al(1) 
procollagen gene (29). In addition, a sequence similar  to  the 
AP-1-binding site (5"GAGTCC) is located in reverse  orienta- 
tion at -165 bp, and a sequence of perfect identity with a 
binding site for an Spl-like factor from the GC2 cis-acting 
element of the rat growth  hormone and  the  F2  element of the 
human growth  hormone genes (GGGAGGAG) is found at -148 
bp in  reverse  orientation  (45). When  sequences in  the -170 to 
-80 bp region of the  human al(1) procollagen promoter homolo- 
gous to  these consensus  binding sites were examined in elec- 
trophoretic mobility shift  assays, only the  Spl.1 probe (corre- 
sponding to the sequence  identical  with GC2 and F2) 
demonstrated  increased DNA-protein complex formation with 
nuclear  extracts from TGFpl-treated when compared with un- 
treated fibroblasts. The formation of the  R1 complex was abol- 
ished or decreased in competition assays with all  three  Spl- 
related oligonucleotides, in  contrast  to  the R2 complex, which 
was prevented only by the  Spl.1 oligonucleotide competitor. 
These  observations suggest  that  at  least one component of the 
R1 complex may be a  member of the  Spl family of transcription 
factors. Of interest  in  this  regard  is  the previous demonstration 
that  Spl interacted  with cis-acting elements  within  the  first 
intron  (34) or the promoter  (61) of the al(1) procollagen gene. 
Spl,  originally  described as a factor required for SV40 tran- 
scription,  binds to "GC boxes," which are found in  the promot- 
ers of many  mammalian genes  (44).  Although  ubiquitously ex- 
pressed, recent evidence points to transcriptional regulation as 
an important role for Spl  (62). Overexpression of Spl  was 
shown to  inhibit mouse al(1) procollagen promoter  activity in 
transiently  transfected  NIW3T3 cells (29). However, when co- 
transfected  into Drosophila melanogaster Schneider L2 cells, 
which are devoid of homologs of mammalian  transcription fac- 
tors, Sp l  overexpression caused potent  trans-activation of the 
al(1) procollagen promoter (63). 
In the rat al(1) and the mouse a2(I) procollagen genes, 
TGFP-responsive elements resembling the  NF-1 consensus  se- 
quence have been described (64, 65). In  the rat al(1) procolla- 
gen  gene, the  putative "TGFp activating element"  was  reported 
to be located 1.6 kb  upstream from the  transcription start site 
(65). The  element contains the 3' portion of the canonical NF-1 
sequence GCCAAG also found in the mouse a2(I) promoter. 
However, in contrast to the mouse a2(1) procollagen gene, 
stimulation of rat al(1) procollagen gene  expression by TGFpl 
does not apear to involve NF-1 binding to its cognate DNA 
element (66). Analysis of the nucleotide sequence of the  human 
al(1) procollagen gene indicates that a NF-1-like sequence 
similar  to  the  rat  TGFp  activating  element is located at -1718 
bp (5'-TGCCCACGGCCAGC). However, our results indicate 
that deletion of a 1.5 kb  fragment including this  element did 
not  prevent stimulation of promoter  activity by TGFpl (Fig. 41, 
suggesting that  in NIW3T3 cells this NF-1-like element  is not 
involved in TGFpl-induced transcriptional activation of the 
al(1) procollagen gene. The nature of trans-acting factors, 
which are implicated in the modulation of the expression of 
diverse TGFP-responsive genes, is not completely understood. 
Recent studies  suggest  that, depending on the cell type and  the 
gene that  is  regulated, a variety of distinct  nuclear proteins 
may be involved (67). Moreover, transcriptional regulation by 
TGFp is likely to be a complex process, associated with  the 
combinatorial interactions of ubiquitous and inducible trans- 
acting factors. The identification of cell-specific DNA binding 
factors and of the stimulatory and inhibitory cis-acting ele- 
ments  in  the promoter of the  human al(1) procollagen gene  that 
are  targets for these factors will permit a better  understanding 
of the complex mechanisms that modulate the  transcriptional 
activity of collagen genes during physiologic processes of devel- 
opment and  repair as well as  in a  variety of diseases  charac- 
terized by excessive collagen production. 
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